NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company stated that site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.
This development is significant because NV-387 is a broad-spectrum antiviral candidate that has also been proposed for evaluation against Ebola virus infections. The company noted that the shipment makes the drug locally available should it be utilized in response efforts. NanoViricides believes successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola. The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC.
For more details, the full press release is available at https://ibn.fm/CTIZc.
The company's lead drug candidate, NV-387, is a nanoviricide drug that does not encapsulate remdesivir, while another candidate, NV-CoV-2-R, encapsulates remdesivir. NanoViricides holds a worldwide exclusive perpetual license to TheraCour nanomedicine technology for several drugs targeting specific viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Influenza, Dengue, Ebola, and certain Coronaviruses.
The successful advancement of NV-387 into Phase II trials marks a crucial step for the company, which is also developing drugs against other viral diseases such as oral and genital herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. As with any drug development, there is no assurance that NV-387 will show sufficient effectiveness and safety for human clinical development or lead to a successful pharmaceutical product.
For the latest news and updates on NanoViricides, visit the company's newsroom at https://ibn.fm/NNVC.
